EUVIMEDEUVIMED entdecken
Korrektur

Corrigendum to “Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma” [Eur J Cancer 234 (2026) 116200]

Rasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, Adam Andrzej Luczak, Mario Presti, Inge Marie Svane, Henrik Schmidt, Lars Bastholt, Marco Donia, Eva Ellebaek

European Journal of Cancer · 2026-06 · 242 · 116780

DOI: 10.1016/j.ejca.2026.116780 ↗

Kurz gefasst

Korrektur in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Rasmus Haunstrup Døssing und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls vej 11, Herlev 2730, Denmark.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls vej 11, Herlev 2730, Denmark.
  • Department of Oncology, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, Aarhus N 8200, Denmark.
  • Department of Oncology, Odense University Hospital, J.B. Winsløws Vej 4, Odense C 5000, Denmark.
  • Department of Oncology, Aalborg University Hospital, Hobrovej 18-22, Aalborg 9000, Denmark.
  • Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls vej 11, Herlev 2730, Denmark. Electronic address: eva.ellebaek.steensgaard@regionh.dk.

Zitieren

APA

Døssing, R. H., Hesselberg, E., Clausen, A. B., Luczak, A. A., Presti, M., Svane, I. M., Schmidt, H., Bastholt, L., Donia, M., & Ellebaek, E. (2026). Corrigendum to “Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma” [Eur J Cancer 234 (2026) 116200]. European Journal of Cancer, 242, 116780. https://doi.org/10.1016/j.ejca.2026.116780

Vancouver

Døssing RH, Hesselberg E, Clausen AB, Luczak AA, Presti M, Svane IM, et al. Corrigendum to “Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma” [Eur J Cancer 234 (2026) 116200]. European Journal of Cancer. 2026;242:116780. doi:10.1016/j.ejca.2026.116780

BibTeX
@article{Dssing2026,
  author = {Døssing, Rasmus Haunstrup and Hesselberg, Elisabeth and Clausen, Anna Burton and Luczak, Adam Andrzej and Presti, Mario and Svane, Inge Marie and Schmidt, Henrik and Bastholt, Lars and Donia, Marco and Ellebaek, Eva},
  title = {Corrigendum to “Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma” [Eur J Cancer 234 (2026) 116200]},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {242},
  pages = {116780},
  doi = {10.1016/j.ejca.2026.116780}
}
Kostenlos starten →